MAP2K7 and cancer: Therefore, it would be more beneficial combining anti-PD1/L1 with another anti-cancer agent, such as chemotherapy for SCLC and TNBC, with TKI for RCC and HCC, and with anti-LAG3 or a BRAF/MEK inhibitor for melanoma.